These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9437470)

  • 1. Approval of dolasetron expands antiemetic choices.
    Am J Health Syst Pharm; 1998 Jan; 55(1):18, 20. PubMed ID: 9437470
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Writers challenge points made in article about antiemetic therapy.
    Carroll-Johnson RM
    Oncol Nurs Forum; 2003; 30(6):892; author reply 892. PubMed ID: 14608986
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
    Yeilding A; Bertoli L; Eisenberg P; Plezia P; Modiano MR; Alberts DS; Khojasteh A; Cramer MB; Hahne WF
    Am J Clin Oncol; 1996 Dec; 19(6):619-23. PubMed ID: 8931684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
    Grote TH; Pineda LF; Figlin RA; Pendergrass KB; Hesketh PJ; Karlan BY; Reeves JA; Porter LL; Benedict CR; Hahne WF
    Cancer J Sci Am; 1997; 3(1):45-51. PubMed ID: 9072308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
    Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
    J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
    Danner K; Becker HG; Best B; Madler C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolasetron for chemo nausea.
    Eremita D
    RN; 2001 Mar; 64(3):38-40. PubMed ID: 11288648
    [No Abstract]   [Full Text] [Related]  

  • 10. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
    Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
    J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolasetron: a new option for nausea and vomiting.
    Ogilvie GK
    J Am Anim Hosp Assoc; 2000; 36(6):481-3. PubMed ID: 11105883
    [No Abstract]   [Full Text] [Related]  

  • 15. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of postoperative nausea and vomiting with dolasetron versus ondansetron: is there a conflict of interest?
    White PF
    Anesth Analg; 2005 Dec; 101(6):1887. PubMed ID: 16301287
    [No Abstract]   [Full Text] [Related]  

  • 17. [Value of dolasetron mesilate in treatment of postoperative nausea and vomiting].
    Badaoui R; Yagoubi A; Carpentier F; Riboulot M; Ossart M
    Presse Med; 2000 May; 29(17):947. PubMed ID: 10855246
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy.
    Falkson CI; Falkson HC
    Oncology; 1995; 52(5):427-31. PubMed ID: 7637962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of postoperative nausea and vomiting after hysterectomy with oral dolasetron, intravenous dehydrobenzperidol or a combination of both substances].
    Triem JG; Piper SN; Maleck WH; Schenck A; Schmidt CC; Boldt J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Jun; 34(6):340-4. PubMed ID: 10429771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of post-operative nausea and vomiting. Randomised comparison of dolasetron versus dolasetron plus dexamethasone].
    Piper SN; Triem JG; Röhm KD; Kranke P; Maleck WH; Boldt J
    Anaesthesist; 2003 Feb; 52(2):120-6. PubMed ID: 12624696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.